CN107308160A - 一种抗衰老组合物 - Google Patents
一种抗衰老组合物 Download PDFInfo
- Publication number
- CN107308160A CN107308160A CN201710403792.0A CN201710403792A CN107308160A CN 107308160 A CN107308160 A CN 107308160A CN 201710403792 A CN201710403792 A CN 201710403792A CN 107308160 A CN107308160 A CN 107308160A
- Authority
- CN
- China
- Prior art keywords
- parts
- content
- apolexis composition
- composition according
- resveratrol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 30
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 19
- 239000011777 magnesium Substances 0.000 claims abstract description 19
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 15
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 14
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 14
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 14
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 14
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 14
- 229940016667 resveratrol Drugs 0.000 claims abstract description 14
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 14
- 235000005152 nicotinamide Nutrition 0.000 claims description 14
- 239000011570 nicotinamide Substances 0.000 claims description 14
- 229960003966 nicotinamide Drugs 0.000 claims description 13
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 8
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 8
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 8
- 229940004916 magnesium glycinate Drugs 0.000 claims description 8
- AACACXATQSKRQG-UHFFFAOYSA-L magnesium;2-aminoacetate Chemical compound [Mg+2].NCC([O-])=O.NCC([O-])=O AACACXATQSKRQG-UHFFFAOYSA-L 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 229960003237 betaine Drugs 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 229930195722 L-methionine Natural products 0.000 claims description 4
- 229930003779 Vitamin B12 Natural products 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 4
- 229960004452 methionine Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000019163 vitamin B12 Nutrition 0.000 claims description 4
- 239000011715 vitamin B12 Substances 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 2
- 241000335053 Beta vulgaris Species 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 229940014144 folate Drugs 0.000 claims description 2
- 235000019504 cigarettes Nutrition 0.000 claims 2
- IEYKOZAAGCPPQF-RGMNGODLSA-N [Mg].C(CC)N[C@@H](CCO)C(=O)O Chemical compound [Mg].C(CC)N[C@@H](CCO)C(=O)O IEYKOZAAGCPPQF-RGMNGODLSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 16
- 230000003712 anti-aging effect Effects 0.000 abstract description 14
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract description 12
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 abstract description 12
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 230000008439 repair process Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 17
- 239000004472 Lysine Substances 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- -1 polyphenol compound Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 229940026534 resveratrol 50 mg Drugs 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 101000583239 Homo sapiens Nicotinate-nucleotide pyrophosphorylase [carboxylating] Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 4
- 102100030830 Nicotinate-nucleotide pyrophosphorylase [carboxylating] Human genes 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010041191 Sirtuin 1 Proteins 0.000 description 3
- 102000000344 Sirtuin 1 Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000005257 cortical tissue Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940079330 tryptophan 1000 mg Drugs 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102100036568 Cell cycle and apoptosis regulator protein 2 Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101000933342 Homo sapiens BMP/retinoic acid-inducible neural-specific protein 1 Proteins 0.000 description 2
- 101000715194 Homo sapiens Cell cycle and apoptosis regulator protein 2 Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- JOUIQRNQJGXQDC-AXTSPUMRSA-N namn Chemical compound O1[C@@H](COP(O)([O-])=O)[C@H](O)[C@@H](O)[C@@H]1[N+]1=CC=CC(C(O)=O)=C1 JOUIQRNQJGXQDC-AXTSPUMRSA-N 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 108090000277 nicotinate-nucleotide diphosphorylase (carboxylating) Proteins 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及保健品技术领域，特别涉及一种抗衰老组合物。包括以下重量份数组份：烟酸3‑5份，甲基供应体1‑9份，色氨酸15‑20份或喹啉酸8‑10份，白藜芦醇0.3‑0.5份，可溶性镁8‑10份。本发明含有各种组份的组合可以有效提高体内NAD+的水平，从而维持PARP1不被破坏。白藜芦醇则是从另外一个角度通过增强PARP1的效果来进一步增强人体内基因修复的效果，最终达到强效抗衰老的目的。
Description
（一）技术领域
本发明涉及保健品技术领域，特别涉及一种抗衰老组合物。
（二）背景技术
人口老龄化的问题向来是世界各国学者关注的一个共同焦点。目前，世界上在亚洲生活的老年人占到了全世界老年人数量一半以上(占54％)，其次是欧洲(22％)，根据联合国专题项目的研究估算，2050年每5个人中将会有一位老年人，到2150年，每3个人中就会有一位老年人。延缓衰老、健康长寿是全世界美好的愿望，人类对抗衰老的研究从未停止过。通过对衰老、抗衰老的研究，志在能够延缓衰老的过程，避免、减少老年病的发生，使老年人能健康生活，并提高老年人生活质量。
迄今为止，关于衰老机制的学说和假设已有数百种，譬如自由基学说、免疫机能退化学说、神经内分泌学说、蛋白质合成差错积累学说等，以及近年来基于分子水平和基因水平提出的基因调控学说、DNA损伤修复学说、线粒体损伤学说、端粒酶学说等。然而应用于抗衰老的产品并不多，目前市面上的抗衰老产品多数为食品或中药的提取物组合而成一定程度上具有增强人体机能的作用，但是使用效果并不理想，抗衰老效果有待加强。
（三）发明内容
本发明克服了现有技术存在的不足，提供了一种抗衰老组合物。
本发明是通过如下技术方案实现的：
一种抗衰老组合物，其特征在于：包括以下重量份数组份：烟酸3-5份，甲基供应体1-9份，色氨酸15-20份或喹啉酸8-10份，白藜芦醇0.3-0.5份，可溶性镁8-10份。
还包括烟酰胺核糖1-3份和/或烟酰胺单核苷酸0.5-1份。
其中，烟酰胺核糖含量不大于500mg，例如可以为，但不限于100mg，150mg，200mg,300mg，340mg，400mg，460mg或者480mg等；烟酰胺单核苷酸含量不大于100mg，例如可以为，但不限于50mg，65mg，75mg,80mg，94mg，97mg，或者98mg等。
其中，所述烟酸含量不大于500mg，例如可以为，但不限于100mg，150mg，220mg,320mg，370mg，400mg，470mg或者500mg等。
其中，所述白藜芦醇含量不大于50mg，例如可以为，但不限于10mg，15mg，20mg,30mg，33mg，40mg，45mg或者49mg等。
其中，所述可溶性镁含量不大于500mg，例如可以为，但不限于100mg，150mg，220mg,320mg，370mg，400mg，470mg或者500mg等。
其中，所述甲基供应体包括L-蛋氨酸，胆碱，甜菜碱，叶酸，维生素B12，中的一种或两种的混合；
其中L-蛋氨酸含量不超过500mg，例如可以为，但不限于100mg，150mg，220mg,320mg，370mg，400mg，470mg或者500mg等；
胆碱含量不超过400mg，例如可以为，但不限于150mg，220mg,320mg，370mg，400mg等；
甜菜碱含量不超过100mg，例如可以为，但不限于65mg，68mg，75mg,80mg，90mg或者100mg等；
叶酸含量不超过200mg，例如可以为，但不限于100mg，130mg，145mg,155mg，170mg，190mg，或者200mg等；
维生素B12含量不超过500微克；
其中，所述可溶性镁包括甘氨酸镁，赖氨酸镁中的一种或其混合。
抗衰老组合物为口服制剂，包括片剂、胶囊剂、口服液。
人体在生长过程中，DNA不断分裂复制，人体中存在一种修复人体DNA的蛋白质PARP1，蛋白质PARP1可以修复人体DNA，然而经过研究发现在人体生长的过程中PARP1逐渐被一种叫做DBC1的蛋白质侵蚀而逐渐失去修复DNA的能力，而修复DNA能力的减弱是目前导致衰老的主流理论之一。
本发明中的烟酸和烟酰胺核糖可以在人体中通过不同的酶催化生成烟酰胺单核苷酸，烟酰胺单核苷酸（NMN）可以经过一步酶反应生成烟酰胺腺嘌呤二核苷酸（NAD+），而NAD+则可以抑制DBC1与PARP1起反应。
白藜芦醇是多酚类化合物，主要来源于花生、葡萄（红葡萄酒）、虎杖、桑椹等植物。白藜芦醇是一种生物性很强的天然多酚类物质，又称为芪三酚；白藜芦醇具有抗肿瘤作用，降低血压和降低心血管病的风险，抗氧化、抗自由基作用，抗菌作用，抗衰老作用，雌激素作用，对免疫系统的调节作用等；本申请中添加有白藜芦醇具有增强PARP1蛋白质的效果的作用。
色氨酸（tryptophan）经过一系列内部反应生成喹啉酸，而喹啉酸被QAPRTase酶催化生成NAMN，最终生成NAD+；但QPRT酶的容量有限，外界补充的色氨酸和喹啉酸在QPRT酶活性不足的情况下无法有效转化成为NAD+，因此仅仅补充色氨酸或者喹啉酸难以有效提高NAD+含量，本发明中同时添加有可溶性镁，由于添加可溶性镁后，可以进一步激活QPRT酶活性，然而添加可溶性镁的量需要控制，添加过少不能充分激发QPRT酶活性，同时也不能添加过多；
在NAD+辅助抗衰老蛋白质SIRT1和修复基因蛋白质PARP1的过程中会不断生成烟酰胺（nicotinamide），烟酰胺是SIRT1和PARP1的抑制剂，过度堆积会导致抗衰老蛋白质SIRT1和PARP1活性下降。而烟酰胺通过体内代谢变成N-甲基4吡啶酮3甲酰胺和N-甲基2吡啶酮5甲酰胺，这两个反应都需要大量甲基参与反应。为防止烟酰胺堆积对两种蛋白质活性造成影响，加入甲基供体可以加速乙酰胺代谢进程。
本发明优点：本发明含有各种组份的组合可以有效提高体内NAD+的水平，从而维持PARP1不被破坏。白藜芦醇则是从另外一个角度通过增强PARP1的效果来进一步增强人体内基因修复的效果，最终达到强效抗衰老的目的。
（四）具体实施方式
实施例1：
将色氨酸1000mg或者喹啉酸800mg，甘氨酸镁或赖氨酸镁400mg，烟酸400mg，乙酰胺核苷200mg和/或乙酰胺单核苷酸80mg，白藜芦醇50mg ，叶酸100mg经混合，制粒，干燥，压片，制得抗衰老药物片剂。
实施例2：
将色氨酸2000mg或者喹啉酸1000mg ，甘氨酸镁和赖氨酸镁500mg，烟酸500mg，乙酰胺核苷300mg和/或乙酰胺单核苷酸100mg，白藜芦醇50mg，叶酸200mg经混合，制粒，干燥，压片，制得抗衰老药物片剂。
实施例3：
将色氨酸1000mg或者喹啉酸800mg，甘氨酸镁或赖氨酸镁400mg，烟酸400mg，乙酰胺核苷200mg和/或乙酰胺单核苷酸80mg，白藜芦醇50mg ，甜菜碱80mg，加入占总质量50%-60%的微晶纤维素，混合均匀，喷入95％乙醇溶液， 制软材，过50目筛制粒，干燥后分装于胶囊中，制得胶囊剂。
实施例4：
将色氨酸2000mg或者喹啉酸1000mg ，甘氨酸镁和赖氨酸镁500mg，烟酸500mg，乙酰胺核苷300mg和/或乙酰胺单核苷酸100mg，白藜芦醇50mg，甜菜碱100mg，加入占总质量50%-60%的微晶纤维素，混合均匀，喷入95％乙醇溶液， 制软材，过50目筛制粒，干燥后分装于胶囊中，制得胶囊剂。
实施例5：
将色氨酸1000mg或者喹啉酸800mg，甘氨酸镁或赖氨酸镁400mg，烟酸400mg，乙酰胺核苷200mg和/或乙酰胺单核苷酸80mg，白藜芦醇50mg ，叶酸和甜菜碱共200mg，经混合，加入常规量的防腐剂，稳定剂等辅料；过滤、灭菌后分装10mL瓶中，制成口服液。
实施例6：
将色氨酸2000mg或者喹啉酸1000mg ，甘氨酸镁和赖氨酸镁500mg，烟酸500mg，乙酰胺核苷300mg和/或乙酰胺单核苷酸100mg，白藜芦醇50mg，经混合，加入常规量的防腐剂，稳定剂等辅料；过滤、灭菌后分装10mL瓶中，制成口服液。
应用实施例2对本发明NAD+提高水平检测，具体如下：
选取体重180～220g小鼠60只，雌雄各半，随机分为6组，每组10只，第一组饲喂实施例按小鼠体重调整过剂量的2的片剂，第二组饲喂仅含有烟酸的片剂，第三组饲喂仅含有烟酰胺核糖的片剂，第四组饲喂仅含有白藜芦醇的片剂，第五组饲喂相对于实施例2不含有色氨酸或者喹啉酸，第六组相对于实施例2不含有可溶性镁，第七组饲喂含有SOD成分片剂，第八组不饲喂任何额外的物质；将雌鼠雄鼠分笼饲养。试验期间食物及水供应足量。饲喂1个星期后，以脱臼法处死小白鼠，分别取小鼠骨骼肌肉组织、肝脏组织和大脑皮层组织测定NAD+水平，采用HPLC进行检测；
骨骼肌肉组织中 NAD的提取方法是：
称取约0.1g骨骼肌肉组织，加入0.9mL酸性提取液，冰浴研磨，煮沸5min；冰浴中冷却后，10000g4℃离心10min；取上清液至另一新的离心管中，加入等体积的碱性提取液使之中和，10000g4℃离心10min，取上清液冰上保存待测。
其中，肝脏组织中NAD的提取方法是：
称取约0.1g肝脏组织，加入0.9mL酸性提取液，冰浴研磨，煮沸5min；冰浴中冷却后，10000g4℃离心10min；取上清液至另一新的离心管中，加入等体积的碱性提取液使之中和，10000g4℃离心10min，取上清液冰上保存待测。
其中，大脑皮层组织中NAD的提取方法是：
称取约0.1g大脑皮层组织，加入0.9mL酸性提取液，冰浴研磨，煮沸5min；冰浴中冷却后，10000g4℃离心10min；取上清液至另一新的离心管中，加入等体积的碱性提取液使之中和，10000g4℃离心10min，取上清液冰上保存待测。
检测结果如下：
从上表可以看出，单独服用色氨酸或喹啉酸，烟酸，烟酰胺核糖，白藜芦醇对体内的NAD+提高水平有限，难以达到抗衰老的效果，而色氨酸或喹啉酸，烟酸，烟酰胺核糖，白藜芦醇按比例配合后NAD+水平明显提高，然而其提高效果明显小于实施例2的组合物提高效果，而通过实施例2与对比例6对比可知，没有添加可溶性镁的组合物对NAD+的提高效果有所抑制；本发明组合物可以有效提高的NAD+水平可以维持人类修复DNA的能力，从而延缓衰老。而服用SOD成分片剂虽然抗衰老的功能，但是对身体NAD+水平的提高没有明显作用。
尽管已用具体实施例来说明和描述了本发明，然而应意识到，在不背离本发明的精神和范围的情况下可以作出许多其它的更改和修改。 因此， 这意味着在所附权利要求中包括属于本发明范围内的所有这些变化和修改。
Claims (9)
1.一种抗衰老组合物，其特征在于：包括以下重量份数组份：烟酸3-5份，甲基供应体1-9份，色氨酸15-20份或喹啉酸8-10份，白藜芦醇0.3-0.5份，可溶性镁8-10份。
2.根据权利要求1所述的抗衰老组合物，其特征在于：还包括烟酰胺核糖1-3份和/或烟酰胺单核苷酸0.5-1份。
3.根据权利要求2所述的抗衰老组合物，其特征在于：烟酰胺核糖含量不大于500mg，烟酰胺单核苷酸含量不大于100mg。
4.根据权利要求1所述的抗衰老组合物，其特征在于：所述烟酸含量不大于500mg。
5.根据权利要求1所述的抗衰老组合物，其特征在于：所述白藜芦醇含量不大于50mg。
6.根据权利要求1所述的抗衰老组合物，其特征在于：所述可溶性镁含量不大于500mg。
7.根据权利要求1所述的抗衰老组合物，其特征在于：所述甲基供应体包括L-蛋氨酸，胆碱，甜菜碱，叶酸，维生素B12，中的一种或两种的混合，其中L-蛋氨酸含量不超过500mg，胆碱含量不超过400mg，甜菜碱含量不超过100mg，叶酸含量不超过200mg，维生素B12含量不超过500微克。
8.根据权利要求1所述的抗衰老组合物，其特征在于：所述可溶性镁包括甘氨酸镁，赖氨酸镁中的一种或其混合。
9.根据权利要求1-8任意一项所述的抗衰老组合物，其特征在于：抗衰老组合物为口服制剂，包括片剂、胶囊剂、口服液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710403792.0A CN107308160A (zh) | 2017-06-01 | 2017-06-01 | 一种抗衰老组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710403792.0A CN107308160A (zh) | 2017-06-01 | 2017-06-01 | 一种抗衰老组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107308160A true CN107308160A (zh) | 2017-11-03 |
Family
ID=60183989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710403792.0A Pending CN107308160A (zh) | 2017-06-01 | 2017-06-01 | 一种抗衰老组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107308160A (zh) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045037A (zh) * | 2018-08-01 | 2018-12-21 | 董玲 | 一种提升辅酶ⅰ的抗衰老组合物、制剂及其制备方法 |
| CN109566826A (zh) * | 2018-10-15 | 2019-04-05 | 河南省锐达医药科技有限公司 | 一种抗衰老提高免疫力美容的组合物 |
| CN109953899A (zh) * | 2019-03-06 | 2019-07-02 | 浙江纳巍负离子科技有限公司 | 促年轻态负离子富勒烯多效复方补充剂及制备方法 |
| WO2019175587A1 (en) * | 2018-03-13 | 2019-09-19 | Nuchido Limited | Compositions |
| CN110251493A (zh) * | 2019-07-16 | 2019-09-20 | 刘兆麒 | 一种抗衰老组合物及其用途 |
| WO2020016543A3 (en) * | 2018-03-13 | 2020-03-12 | Nuchido Limited | Treatment of diseases involving nad |
| CN112089705A (zh) * | 2020-09-28 | 2020-12-18 | 深圳雾件科技有限公司 | 一种烟酰胺单核苷酸微囊及其制备方法 |
| CN112206237A (zh) * | 2019-07-10 | 2021-01-12 | 杨维稼 | 一种含有牛磺酸锌的抗衰老组合物、制备方法及其应用 |
| CN113082130A (zh) * | 2021-04-28 | 2021-07-09 | 上海滇亿科技工贸有限公司 | 一种含nad+的抗衰老组合物 |
| CN113329988A (zh) * | 2019-01-21 | 2021-08-31 | 未来食品有限责任公司 | 甲基化工艺 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040905A (zh) * | 2012-01-16 | 2013-04-17 | 四川师范大学 | 雪灵芝或其提取物在制备抗衰老的药物或保健食品中的用途 |
| CN106036823A (zh) * | 2016-05-23 | 2016-10-26 | 沈阳迪格医疗科技有限公司 | 一种保健品及其制备方法 |
-
2017
- 2017-06-01 CN CN201710403792.0A patent/CN107308160A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103040905A (zh) * | 2012-01-16 | 2013-04-17 | 四川师范大学 | 雪灵芝或其提取物在制备抗衰老的药物或保健食品中的用途 |
| CN106036823A (zh) * | 2016-05-23 | 2016-10-26 | 沈阳迪格医疗科技有限公司 | 一种保健品及其制备方法 |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111918670A (zh) * | 2018-03-13 | 2020-11-10 | 努其杜有限公司 | 组合物 |
| JP2021515796A (ja) * | 2018-03-13 | 2021-06-24 | ヌチド リミテッド | 組成物 |
| WO2019175587A1 (en) * | 2018-03-13 | 2019-09-19 | Nuchido Limited | Compositions |
| GB2586745B (en) * | 2018-03-13 | 2023-04-05 | Nuchido Ltd | Compositions |
| WO2020016543A3 (en) * | 2018-03-13 | 2020-03-12 | Nuchido Limited | Treatment of diseases involving nad |
| GB2586746A (en) * | 2018-03-13 | 2021-03-03 | Nuchido Ltd | Treatment of diseases involving NAD |
| GB2586745A (en) * | 2018-03-13 | 2021-03-03 | Nuchido Ltd | Compositions |
| CN109045037A (zh) * | 2018-08-01 | 2018-12-21 | 董玲 | 一种提升辅酶ⅰ的抗衰老组合物、制剂及其制备方法 |
| CN109566826A (zh) * | 2018-10-15 | 2019-04-05 | 河南省锐达医药科技有限公司 | 一种抗衰老提高免疫力美容的组合物 |
| CN113329988A (zh) * | 2019-01-21 | 2021-08-31 | 未来食品有限责任公司 | 甲基化工艺 |
| CN109953899A (zh) * | 2019-03-06 | 2019-07-02 | 浙江纳巍负离子科技有限公司 | 促年轻态负离子富勒烯多效复方补充剂及制备方法 |
| CN112206237A (zh) * | 2019-07-10 | 2021-01-12 | 杨维稼 | 一种含有牛磺酸锌的抗衰老组合物、制备方法及其应用 |
| CN110251493A (zh) * | 2019-07-16 | 2019-09-20 | 刘兆麒 | 一种抗衰老组合物及其用途 |
| CN112089705A (zh) * | 2020-09-28 | 2020-12-18 | 深圳雾件科技有限公司 | 一种烟酰胺单核苷酸微囊及其制备方法 |
| CN113082130A (zh) * | 2021-04-28 | 2021-07-09 | 上海滇亿科技工贸有限公司 | 一种含nad+的抗衰老组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107308160A (zh) | 一种抗衰老组合物 | |
| CN103055057B (zh) | 一种与左旋肉碱配伍的植物减肥降脂组合物 | |
| CN109045037A (zh) | 一种提升辅酶ⅰ的抗衰老组合物、制剂及其制备方法 | |
| Mubarak | Effect of red bull energy drink on rats submandibular salivary glands (light and electron microscopic study) | |
| CN104473249A (zh) | 一种松花粉的液体制剂及其制备方法 | |
| CN103300278A (zh) | 含有咪唑肽和槲皮素糖苷的组合物 | |
| JP6228279B2 (ja) | 組成物 | |
| CN106310233A (zh) | 抗氧化抗疲劳祛斑美白保湿解酒排重金属的营养组合物及保健食品 | |
| CN101428037B (zh) | 含修复因子的抗衰老组合物 | |
| JP2007161675A (ja) | 疲労改善内服剤 | |
| CN102028230B (zh) | 一种保健品辅料及其应用 | |
| JP2013070687A (ja) | サラシア属植物抽出物を含有する飲料の製造方法 | |
| JP6055180B2 (ja) | 組成物 | |
| CN107647016A (zh) | 一种多穗柯甜茶与大红袍复配茶及其提取物的制备方法和应用 | |
| EP4245371A1 (en) | Crystalline lens hardness adjustment agent | |
| CN107510701B (zh) | 一种儿童补铁与维生素的组合物及其制备方法和应用 | |
| JP2009269834A (ja) | 骨吸収抑制剤並びに骨吸収抑制用飲食品及び医薬部外品 | |
| JP7496318B2 (ja) | 暑熱ストレス緩和剤 | |
| CN105124702B (zh) | 一种适用于经期女性的补充剂或饮料及其制备方法 | |
| JP7349424B2 (ja) | 組成物 | |
| JP2011063583A (ja) | 眼精疲労改善用組成物 | |
| JP2019218304A (ja) | 経口組成物 | |
| JP2010070463A (ja) | 栄養ドリンク剤 | |
| CN116744936A (zh) | 晶状体硬度调节剂 | |
| JP5854578B2 (ja) | 筋肉増強剤または基礎代謝増強剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171103 |